Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial of ...

As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...

Dynavax has revealed outcomes from the initial part of its Phase I/II trial, comparing its shingles vaccine Z-1018 against ...

This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

Padcev-Keytruda will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.

The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.